M2 Pharma - Research and Development

CrossBridge Bio to be acquired by Eli Lilly

14 April 2026 - CrossBridge Bio Inc, a pre-clinical biotechnology company developing next-generation dual-payload antibody-drug conjugates (ADCs), announced on Tuesday that it has entered into a defin...

IDEAYA Biosciences and Servier report positive results from Phase 2/3 trial of darovasertib/crizotinib combination

14 April 2026 - US precision medicine oncology company IDEAYA Biosciences Inc (NASDAQ:IDYA) and French pharmaceutical company Servier announced on Monday positive topline results from their Phase 2/3 ...

FDA grants priority review to ifinatamab deruxtecan in small cell lung cancer

13 April 2026 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, and Japanese healthcare company Daiichi Sankyo Co Ltd (TYO:4568) announced on Monday th...

EU approves Sanofi and Regeneron's Dupixent for young children with chronic spontaneous urticaria

13 April 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) and US biotechnology company Regeneron Pharmaceuticals Inc (Nasdaq:REGN) announced on Monday that they have rece...

Apotex's generic Ozempic (Semaglutide Injection) receives US FDA tentative approval

13 April 2026 - Canadian pharmaceutical company Apotex Inc announced on Friday that its US subsidiary Apotex Corp has received the first US Food and Drug Administration (FDA) tentative approval for it...

Lupin's Dapagliflozin Tablets launched in US market

13 April 2026 - India-based global pharmaceutical company Lupin Limited (BSE:500257) (NSE:LUPIN) announced on Friday the launch of Dapagliflozin Tablets, 5 mg and 10 mg, in the United States.Lupin...